Literature DB >> 22903263

Comparability of critical quality attributes for establishing biosimilarity.

Jason J Z Liao1, Patrick F Darken.   

Abstract

To develop a biosimilar product, it is essential to demonstrate the biosimilarity between the proposed biosimilar product and the reference product first in terms of quality in a stepwise approach that can then help inform the extent of safety and efficacy data that will be required to establish biosimilarity. These comparability studies should have direct side-by-side comparisons of the test and the reference products. In this paper, we develop a statistical method for unpaired head-to-head quality attribute comparisons. The method uses a plausibility interval derived from comparing the reference against the reference itself as the goalpost for claiming comparability. The idea behind this is that any observed difference between the reference and the reference itself should be considered as the random noise and as a part of the variability. We illustrate the performance of the proposed method by using simulation and real data sets.
Copyright © 2012 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2012        PMID: 22903263     DOI: 10.1002/sim.5564

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Analytical Similarity Assessment in Biosimilar Studies.

Authors:  Shein-Chung Chow; Fuyu Song; He Bai
Journal:  AAPS J       Date:  2016-02-12       Impact factor: 4.009

2.  The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal.

Authors:  Johanna Mielke; Franz Innerbichler; Martin Schiestl; Nicolas M Ballarini; Byron Jones
Journal:  AAPS J       Date:  2018-11-27       Impact factor: 4.009

3.  Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

Authors:  Neh Nupur; Nidhi Chhabra; Rozaleen Dash; Anurag S Rathore
Journal:  MAbs       Date:  2017-12-07       Impact factor: 5.857

4.  A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

Authors:  Haitao Pan; Ying Yuan; Jielai Xia
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2016-12-23       Impact factor: 1.864

5.  Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.

Authors:  Shiwei Miao; Li Fan; Liang Zhao; Ding Ding; Xiaohui Liu; Haibin Wang; Wen-Song Tan
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

6.  An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment.

Authors:  Kejian Wu; Haitao Pan; Chen Li; Qingbo Zhao; Ling Wang; Jielai Xia
Journal:  PLoS One       Date:  2018-12-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.